{"disease":{"id":"transplant-ineligible","name":"transplant ineligible"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07247097","title":"ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT05284591","title":"Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv)","phase":"","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"iOMEDICO AG","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}